article thumbnail

Compliant Science: The Critical Role of Compliance for Medical Affairs

H1 Blog

For more information on how to build effective and compliant engagement plans, download our white paper: How AI Can Save Medical Affairs from Drowning in Data. It is a vital component in building trust and maintaining ethical standards in the healthcare industry.

article thumbnail

Keeping tabs on Covid-19: Starpharma creates slow release remdesivir nanoparticl…

The Pharma Data

In an effort to slow the spread of the disease and prevent a second wave, pharma companies around the world are continuously looking to advance new methods of treatment. This week’s round up dives into developments from companies based in Australia and the US. Saama Technologies, Inc. ,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 10 Drug Discovery Trends at the Top 20 Pharma

PerkinElmer

Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. A PerkinElmer White Paper offers a detailed look at the findings. Small molecules are making a comeback.

article thumbnail

Keeping tabs on Covid-19: BetterLife embraces virtual clinical trials and Novan shares positive results from in vitro antiviral technology against SARS-CoV-2

The Pharma Data

As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. Download Medidata’s white paper to learn how to virtualize clinical trials and bring new therapies closer to patients. Source link.

article thumbnail

Listicle: Maximising outsourcing models beyond time and cost

Drug Discovery World

For these reasons and others, many biotech and pharmaceutical companies – along with government research labs and academic institutions – rely on contract research organizations (CROs) for drug discovery services. Big pharma companies routinely maintain their own decks of upwards of millions of compounds.